Cantor Fitzgerald Downgrades Alcobra Ltd. (ADHD) to Hold
- Wall St lackluster ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains on euro with Fed's Waller hawkish on rates
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Timken (TKR) Appoints Tarak Mehta as New CEO
Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study
September 28, 2016 8:01 PM EDTTEL AVIV, Israel, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM: ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it has received verbal notice from the Division of Psychiatry Products of the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on its Investigational New Drug (IND) applications for MDX in ADHD and Fragile X Syndrome. The clinical hold affects Alcobras ongoing Phase III... More